Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio sul Buntanetap in partecipanti con PD

28 ottobre 2026 aggiornato da: Annovis Bio Inc.

Uno Studio Clinico in Aperto che Indaga la Sicurezza a Lungo Termine di Buntanetap nel Trattamento di Partecipanti con Malattia di Parkinson

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Panoramica dello studio

Descrizione dettagliata

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

Tipo di studio

Interventistico

Iscrizione (Stimato)

500

Fase

  • Fase 2
  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Alabama
      • Birmingham, Alabama, Stati Uniti, 35233
        • Reclutamento
        • University of Alabama at Birmingham
        • Contatto:
        • Investigatore principale:
          • Natividad Stover, M.D.
    • Arizona
      • Sun City, Arizona, Stati Uniti, 85351
        • Reclutamento
        • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
        • Investigatore principale:
          • Sara Dhanani, M.D.
        • Contatto:
    • California
      • Fountain Valley, California, Stati Uniti, 92708
        • Reclutamento
        • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
        • Investigatore principale:
          • Daniel Truong, M.D.
        • Contatto:
          • Evan Moreno-Davis
          • Numero di telefono: 714-378-5074
          • Email: evan@pmdi.org
    • Colorado
      • Englewood, Colorado, Stati Uniti, 80113
        • Reclutamento
        • Cenexel Rocky Mountain Clinical Research
        • Contatto:
        • Investigatore principale:
          • Meagen Salinas, M.D.
    • Connecticut
      • Stamford, Connecticut, Stati Uniti, 06824
        • Reclutamento
        • New England Institute for Clinical Research (Ki Health Partners)
        • Contatto:
        • Investigatore principale:
          • Peter McAllister, M.D.
    • Florida
      • Aventura, Florida, Stati Uniti, 33180
        • Reclutamento
        • First Choice Neurology - Aventura Neurologic Associates
        • Investigatore principale:
          • Jonathan Cross, M.D.
        • Contatto:
      • Daytona Beach, Florida, Stati Uniti, 32117
        • Reclutamento
        • Arrow Clinical Trials
        • Contatto:
        • Investigatore principale:
          • David Billmeier, M.D.
      • DeLand, Florida, Stati Uniti, 32720
        • Reclutamento
        • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
        • Investigatore principale:
          • Bruce Rankin, D.O.
        • Contatto:
      • Miami, Florida, Stati Uniti, 33172
      • Miami, Florida, Stati Uniti, 33015
        • Non ancora reclutamento
        • Ezy Medical Research Co.
        • Contatto:
      • Ocala, Florida, Stati Uniti, 34470
        • Reclutamento
        • Renstar Medical Research
        • Investigatore principale:
          • Annette Nieves, M.D.
        • Contatto:
      • Tampa, Florida, Stati Uniti, 33613
        • Reclutamento
        • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
        • Contatto:
        • Investigatore principale:
          • Robert Hauser, M.D., MBA
      • Winter Park, Florida, Stati Uniti, 32789
        • Reclutamento
        • Conquest Research
        • Contatto:
        • Investigatore principale:
          • Rekha Gandhi, M.D.
    • Georgia
      • Decatur, Georgia, Stati Uniti, 30030
        • Reclutamento
        • iResearch Atlanta
        • Contatto:
        • Investigatore principale:
          • Kimball Johnson, M.D.
    • Indiana
      • Indianapolis, Indiana, Stati Uniti, 46256
        • Reclutamento
        • Josephson Wallack Munshower Neurology, P.C.
        • Investigatore principale:
          • Kristi George, M.D.
        • Contatto:
    • Kansas
      • Kansas City, Kansas, Stati Uniti, 66160
        • Reclutamento
        • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
        • Contatto:
        • Investigatore principale:
          • Rajesh Pahwa, M.D.
    • Michigan
      • Farmington Hills, Michigan, Stati Uniti, 48334
        • Reclutamento
        • Quest Research Institute
        • Investigatore principale:
          • Aaron Ellenbogen, D.O.
        • Contatto:
    • New York
      • New York, New York, Stati Uniti, 10019
        • Reclutamento
        • Mount Sinai Hospital
        • Investigatore principale:
          • Joohi Jimenez-Shahed, M.D.
        • Contatto:
    • North Carolina
      • Durham, North Carolina, Stati Uniti, 27710
        • Reclutamento
        • Duke Department of Neurosurgery
        • Investigatore principale:
          • Kyle Mitchell, M.D.
        • Contatto:
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43210
        • Reclutamento
        • The Ohio State University Wexner Medical Center
        • Investigatore principale:
          • Zachary Jordan, M.D.
        • Contatto:
    • Oklahoma
      • Tulsa, Oklahoma, Stati Uniti, 74136
        • Reclutamento
        • The Movement Disorder Clinic of Oklahoma
        • Contatto:
        • Investigatore principale:
          • Kevin Klos, M.D.
    • Pennsylvania
      • Willow Grove, Pennsylvania, Stati Uniti, 19090
        • Reclutamento
        • Abington Neurology
        • Investigatore principale:
          • David Weisman, M.D.
        • Contatto:
    • South Carolina
      • Charleston, South Carolina, Stati Uniti, 29401
        • Reclutamento
        • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
        • Contatto:
        • Investigatore principale:
          • Vanessa Hinson, M.D., PhD
    • Tennessee
      • Cordova, Tennessee, Stati Uniti, 38018
        • Reclutamento
        • Neurology Clinic, P.C.
        • Contatto:
        • Investigatore principale:
          • Kendrick Henderson, M.D.
      • Memphis, Tennessee, Stati Uniti, 38157
        • Reclutamento
        • Veracity Neuroscience LLC
        • Contatto:
        • Investigatore principale:
          • Mark LeDoux, M.D., PhD
    • Texas
      • Round Rock, Texas, Stati Uniti, 78681
        • Reclutamento
        • Central Texas Neurology
        • Contatto:
        • Investigatore principale:
          • Elizabeth Peckham, M.D.
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22903
        • Reclutamento
        • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
        • Investigatore principale:
          • Binit Shah, M.D.
        • Contatto:
    • Washington
      • Spokane, Washington, Stati Uniti, 99202
        • Reclutamento
        • Inland Northwest Research
        • Investigatore principale:
          • Jason Aldred, M.D.
        • Contatto:
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
        • Reclutamento
        • Medical College of Wisconsin
        • Contatto:
        • Investigatore principale:
          • Karen Blindauer, M.D.

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 40 anni a 85 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.

  3. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    3. Intrauterine device (IUD),

    4. Intrauterine hormone-releasing system (IUS),

    5. Bilateral tubal occlusion,

    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),

    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.

  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  8. Good general health with no disease expected to interfere with the study.

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).

  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.

  5. Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.

  7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).

  8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.

  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.

  12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. A learning disability or developmental delay.

  14. Participants whom the site PI deems to be otherwise ineligible.

  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.

  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Cohort 1 - buntanetap

Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

buntanetap capsules 30 mg by mouth daily

Sperimentale: Cohort 2 - buntanetap

Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

buntanetap capsules 30 mg by mouth daily

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Safety of buntanetap
Lasso di tempo: 36-months of treatment

Safety assessments of participants with PD receiving treatment with buntanetap

36-months of treatment
Adverse Events (AE)
Lasso di tempo: 36-months of treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

36-months of treatment
Treatment Emergent Adverse Events (TEAE)
Lasso di tempo: 36-months of treatment

TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

36-months of treatment
Serious Adverse Events (SAE)
Lasso di tempo: 36-months of treatment

SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

36-months of treatment

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Laurie Sanders, Ph.D., Duke Clinical Research Institute

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 gennaio 2026

Completamento primario (Stimato)

1 settembre 2029

Completamento dello studio (Stimato)

1 novembre 2029

Date di iscrizione allo studio

Primo inviato

26 novembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

9 dicembre 2025

Primo Inserito (Effettivo)

16 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi